Molecular Aspects of Anti-Atherosclerotic Effects of Short Peptides

被引：6

作者：

Khavinson, V. Kh ^{[1
,2
]}

Lin'kova, N. S. ^{[1
]}

Evlashkina, E. V. ^{[1
]}

Durnova, A. O. ^{[3
]}

Kozlov, K. L. ^{[1
]}

Gutop, O. E. ^{[1
]}

机构：

[1] Russian Acad Sci, St Petersburg Inst Bioregulat & Gerontol, St Petersburg 196140, Russia

[2] Russian Acad Sci, IP Pavlov Inst Physiol, St Petersburg 196140, Russia

[3] Russian Acad Med Sci, DO Ott Res Inst Obstet & Gynecol, St Petersburg, Russia

来源：

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2014年 / 158卷 / 01期

关键词：

short peptides; vascular endothelium; aging; atherosclerosis; INFLAMMATION; CELLS;

D O I：

10.1007/s10517-014-2713-8

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

We studied molecular mechanisms of the vasoprotective effects of tripeptide T-38 and dipeptide RR-1. Short peptides T-38 and the RR-1 activate the processes of cell renewal in organotypic and dissociated cultures of vascular cells during aging by increasing the expression of Ki-67 and reducing the synthesis of p53 protein. T-38 and RR-1 reduce the synthesis of E-selectin, adhesion molecule involved in the formation of atherosclerotic plaques.

引用

页码：159 / 163

页数：5

共 50 条

[41] NATURAL PRODUCTS FOR ANTI-ATHEROSCLEROTIC THERAPY
Kirichenko, T.
Orekhova, V.
Myasoedova, V.
Melnichenko, A.
Sobenin, I.
Orekhov, A.
ATHEROSCLEROSIS, 2019, 287 : E152 - E152
[42] ARTIFICIAL HDL AS AN ANTI-ATHEROSCLEROTIC DRUG
OREKHOV, AN
MISHARIN, AY
TERTOV, VV
KHASHIMOV, KA
POKROVSKY, SN
REPIN, VS
SMIRNOV, VN
LANCET, 1984, 2 (8412): : 1149 - 1150
[43] Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
Angelos D. Karagiannis
Martin Liu
Peter P. Toth
Shijia Zhao
Devendra K. Agrawal
Peter Libby
Yiannis S. Chatzizisis
Current Atherosclerosis Reports, 2018, 20
[44] ASTAXANTHIN: AN ANTI-ATHEROSCLEROTIC TREATMENT IN MICE
Anto-Michel, N.
Maechler, H.
Zirlik, A.
ATHEROSCLEROSIS, 2023, 379
[45] New trends in anti-atherosclerotic agents
Napoli, C
Sica, V
Pignalosa, O
de Nigris, F
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (15) : 1755 - 1772
[46] CETABEN SODIUM, AN ANTI-ATHEROSCLEROTIC AGENT
ALBRIGHT, JD
SCHAFFER, SA
SHEPHERD, RG
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (07) : 936 - 937
[47] Anti-atherosclerotic effects of small molecular weight compounds enhancing eNOS expression and preventing eNOS uncoupling
Wohlfart, P.
Xu, H.
Endlich, A.
Habermeier, A.
Closs, E., I
Huebschle, T.
Mang, C.
Strobel, H.
Suzuki, T.
Kleinert, H.
Foerstermann, U.
Ruetten, H.
Li, H.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 377 : 22 - 22
[48] Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation
Karagiannis, Angelos D.
Liu, Martin
Toth, Peter P.
Zhao, Shijia
Agrawal, Devendra K.
Libby, Peter
Chatzizisis, Yiannis S.
CURRENT ATHEROSCLEROSIS REPORTS, 2018, 20 (04)
[49] Fistular onion stalk extract exhibits anti-atherosclerotic effects in rats
He, Benhong
Hao, Jianjun
Sheng, Weiwei
Xiang, Yuancai
Zhang, Jiemeia
Zhu, Hao
Tian, Jingcheng
Zhu, Xu
Feng, Yunxia
Xia, Hao
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (03) : 785 - 792
[50] Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice
Tiyerili, Vedat
Beiert, Thomas
Schatten, Hannah
Camara, Bakary
Jehle, Julian
Schrickel, Jan W.
Nickenig, Georg
Andrie, Rene P.
ATHEROSCLEROSIS, 2016, 251 : 430 - 437

← 1 2 3 4 5 →